Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EPS (Weighted Average and Diluted) (2015 - 2026)

Avalo Therapeutics posted quarterly EPS (Weighted Average and Diluted) of -$0.98 for Q1 2026, up 21.6% year-on-year from -$0.81 in Q1 2025, and down 164.86% on a QoQ basis from -$0.37 in Q4 2025.

Avalo Therapeutics (AVTX) has 11 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.98 in Q1 2026.

  • For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 21.6% year-over-year to -$0.98; the trailing twelve-month figure through Mar 2026 stood at -$5.46 (up 66.77% YoY), and the FY2025 full-year result was -$5.84, up 72.07% from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.98, down from -$0.37 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $117.47 in Q4 2023 and bottomed at -$1059.6 in Q4 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$2.19 (2025), against an average of -$87.07.
  • Peak annual rise in EPS (Weighted Average and Diluted) reached 116.27% in 2022, while the deepest fall reached 54802.07% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1059.6 in 2022, then jumped by 111.09% to $117.47 in 2023, then plunged by 98.54% to $1.72 in 2024, then tumbled by 121.51% to -$0.37 in 2025, then tumbled by 164.86% to -$0.98 in 2026.
  • The last three EPS (Weighted Average and Diluted) figures came in at -$0.98 (Q1 2026), -$0.37 (Q4 2025), and -$2.19 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -4.43
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 4.02
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.51
10 Avalo Therapeutics 317.29 Mn 317.29 Mn - -0.98

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.98
Dec 31, 2025 -0.37
Sep 30, 2025 -2.19
Jun 30, 2025 -1.92
Mar 31, 2025 -1.25
Dec 31, 2024 1.72
Sep 30, 2024 -2.83
Jun 30, 2024 -14.07
Mar 31, 2024 -141.14
Dec 31, 2023 117.47
Sep 30, 2023 -26.83
Jun 30, 2023 -140.73
Mar 31, 2023 -204.00
Dec 31, 2022 -1,059.61
Sep 30, 2022 0.34
Jun 30, 2022 -1.38
Mar 31, 2022 -2.35
Dec 31, 2021 -1.93
Sep 30, 2021 -2.09
Jun 30, 2021 -2.12
Mar 31, 2021 -0.32
Dec 31, 2020 2.52
Sep 30, 2020 -0.16
Jun 30, 2020 -0.93
Mar 31, 2020 -1.78
Dec 31, 2018 -0.02
Sep 30, 2018 -0.71
Dec 31, 2017 -0.11
Sep 30, 2017 0.52
Jun 30, 2017 -0.14
Mar 31, 2017 -0.19
Dec 31, 2016 -0.19
Sep 30, 2016 -0.70
Dec 31, 2015 -1.72